What it's for (Indications)
- Atorvastatin calcium trihydrate + ezetimibe is indicated as an adjunct to diet for the reduction of elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with **primary (heterozygous familial and non-familial) hypercholesterolemia or mixed dyslipidemia**, where combination therapy is considered appropriate.
- This includes patients not adequately controlled with a statin alone, or those already on a statin and ezetimibe as separate tablets.
- It is also indicated for the reduction of elevated LDL-C in adult patients with **homozygous familial hypercholesterolemia (HoFH)**, typically used as an adjunct to other lipid-lowering treatments (e.
- g.
- , LDL apheresis) or if such treatments are unavailable.
- Additionally, this combination may be used to reduce the risk of major cardiovascular events in patients with coronary heart disease (CHD) and a history of acute coronary syndrome (ACS) who are already receiving maximal statin therapy but require additional LDL-C lowering.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of atorvastatin calcium trihydrate + ezetimibe must be individualized based on the patient’s baseline LDL-C levels, the goal of therapy, and patient response. The combination product is available in various strengths, such as atorvastatin 10 mg/ezetimibe 10 mg, atorvastatin 20 mg/ezetimibe 10 mg, atorvastatin 40 mg/ezetimibe 10 mg, and atorvastatin 80 mg/ezetimibe 10 mg. The recommended starting dose depends on the patient's current lipid-lowering regimen and LDL-C targets. For patients not currently on statin therapy, a starting dose like atorvastatin 10 mg/ezetimibe 10 mg once daily may be considered. For patients inadequately controlled on a statin alone, or those already on ezetimibe and a statin, the combination product should be chosen with atorvastatin strength corresponding to the required dose. The maximum recommended dose is atorvastatin 80 mg/ezetimibe 10 mg once daily. The tablets should be administered orally once daily, with or without food, at any time of day, though consistency is advised. Dosage adjustments, if necessary, should be made at intervals of 2 to 4 weeks or more after initiating therapy, or after titration, until the therapeutic goal is achieved, while monitoring lipid parameters and adverse events. |
Safety & Warnings
Common Side Effects
- The most commonly reported adverse reactions associated with atorvastatin calcium trihydrate + ezetimibe therapy typically include gastrointestinal disturbances such as diarrhea, constipation, abdominal pain, nausea, and dyspepsia.
- Other frequent side effects may involve headache, nasopharyngitis, influenza, upper respiratory tract infection, myalgia, and arthralgia.
- While generally well-tolerated, more serious, albeit less common, adverse events can occur.
- These include **myopathy**, characterized by muscle pain, tenderness, or weakness, and its more severe form, **rhabdomyolysis**, which can lead to kidney failure.
- Patients should be counselled to report unexplained muscle symptoms promptly.
- **Hepatotoxicity**, indicated by elevations in liver transaminases, requires monitoring.
- Other potential serious adverse effects include new-onset diabetes mellitus, pancreatitis, hypersensitivity reactions (including rash, pruritus, anaphylaxis, and angioedema), and peripheral neuropathy.
- Cognitive impairment, such as memory loss and confusion, has been rarely reported with statin use.
- Patients experiencing persistent or severe side effects should consult their healthcare provider for evaluation and potential management adjustments.
Serious Warnings
- Black Box Warning: While atorvastatin/ezetimibe combination therapy does not carry a formal FDA Black Box Warning, several serious risks warrant careful consideration and are presented here as a **Serious Warnings** section. **Hepatotoxicity** is a known risk associated with statins, including atorvastatin, necessitating baseline liver function tests and monitoring if clinically indicated. Persistent elevations in serum transaminases (>3 times the upper limit of normal) should lead to discontinuation. **Myopathy and Rhabdomyolysis**, characterized by muscle pain, tenderness, or weakness accompanied by elevated creatine kinase levels (typically >10 times the upper limit of normal), are serious but rare adverse effects. The risk is increased with higher doses, advanced age, renal impairment, hypothyroidism, and co-administration with certain drugs (e.g., strong CYP3A4 inhibitors, gemfibrozil, ciclosporin). Patients should be advised to report unexplained muscle pain immediately. **Fetal harm** is a significant concern; statins are contraindicated in pregnancy and breastfeeding due to the essential role of cholesterol in fetal development. Women of childbearing potential should use effective contraception during treatment. These potential serious adverse events necessitate vigilant patient monitoring and thorough patient education.
- Patients receiving atorvastatin calcium trihydrate + ezetimibe should be closely monitored for potential warnings and precautions.
- **Myopathy and rhabdomyolysis** are serious risks, particularly when co-administered with drugs that significantly inhibit CYP3A4 (e.
- g.
- , ciclosporin, clarithromycin, itraconazole, protease inhibitors), or other lipid-lowering agents like gemfibrozil, other fibrates, or high doses of niacin.
- Concurrent use of fusidic acid is contraindicated.
- Patients should be advised to report any unexplained muscle pain, tenderness, or weakness.
- **Liver enzyme elevations** may occur, and liver function tests should be performed at baseline and if clinically indicated during treatment.
- If persistent transaminase elevations occur (e.
- g.
- , >3 times ULN), the drug should be discontinued.
- Statins, including atorvastatin, have been associated with increases in **HbA1c and fasting serum glucose levels**, indicating a potential for new-onset diabetes mellitus or worsening of pre-existing diabetes in some patients.
- **Interstitial lung disease** has been reported rarely with statins.
- Although not directly caused by the drug, patients with **renal impairment** should be monitored closely as dose adjustment may be necessary.
- Caution is advised in patients with **moderate to severe hepatic impairment** due to increased exposure to ezetimibe.
- This medication is not indicated for women who are pregnant or breastfeeding due to potential fetal harm and excretion into breast milk.
- Cognitive impairment, such as memory loss and confusion, has also been reported rarely with statin use.
How it Works (Mechanism of Action)
Atorvastatin calcium trihydrate + ezetimibe combines two distinct, complementary mechanisms of action to lower elevated cholesterol. **Atorvastatin**, a selective, competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in hepatic cholesterol synthesis, works primarily in the liver. By inhibiting HMG-CoA reductase, atorvastatin reduces the production of mevalonate, a precursor to cholesterol. This reduction in hepatic cholesterol leads to an upregulation of hepatic low-density lipoprotein (LDL) receptors, which in turn increases the uptake and catabolism of circulating LDL-C from the bloodstream. **Ezetimibe** acts at the brush border of the small intestine, specifically inhibiting the absorption of dietary and biliary cholesterol without affecting the absorption of fat-soluble vitamins, triglycerides, or bile acids. It does so by binding to the Niemann-Pick C1-Like 1 (NPC1L1) protein, which is critical for intestinal cholesterol uptake. The combined action of reducing cholesterol synthesis (atorvastatin) and inhibiting cholesterol absorption (ezetimibe) results in a synergistic reduction in LDL-C levels that is greater than either agent alone, providing enhanced efficacy in managing dyslipidemia.